
This study developed a targeted next-generation sequencing panel based on non-exonic single-nucleotide polymorphisms (SNPs) to detect homologous recombination deficiency (HRD) in ovarian cancer tissues. The panel was consistent with whole-genome sequencing in HRD analysis and performed better than SNP microarray in clinical samples. The panel covers 52,592 SNPs and has a high minor allele frequency in Chinese people, making it a promising tool for HRD detection in Chinese patients to guide the use of PARP inhibitors or platinum drugs to treat ovarian and other cancers.
Like
Save
Share